2-氨基-3-羟基丙酸甲酯 | 2104-89-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-3-羟基丙酸甲酯
• 英文名称: Ser-OMe
• 英文别名: Serine methyl ester；methyl 2-amino-3-hydroxypropanoate
• CAS: 2104-89-4
• 化学式: C₄H₉NO₃
• mdl: MFCD00044750
• 分子量: 119.12
• InChiKey: ANSUDRATXSJBLY-UHFFFAOYSA-N

物化性质

• 沸点：
  234.7±20.0 °C(Predicted)
• 密度：
  1.195±0.06 g/cm3(Predicted)
• 保留指数：
  1032;1034;1038

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氨基-3-羟基丙酸甲酯 在 五氯化磷 、 乙酰氯 作用下， 反应 9.0h， 生成 3-氯丙胺酸甲酯
  参考文献：
  名称：

  底物和抑制剂的结构决定因素：用2,4-甲基吡咯烷-2,4-二羧酸盐探测谷氨酸转运蛋白。

  摘要：

  使用分子内[2 + 2]光环化反应，制备了2,4-甲基吡咯烷-2,4-二羧酸盐，作为谷氨酸的构象锁定类似物。该化合物与其他两种吡咯烷二羧酸盐的组合已用于定义区分高亲和力，钠依赖性谷氨酸转运蛋白底物和非底物抑制剂的结构元素。

  DOI：

  10.1016/s0960-894x(98)00560-5
• 作为产物：
  描述：

  DL-丝氨酸 生成 2-氨基-3-羟基丙酸甲酯
  参考文献：
  名称：

  MATHIAS, LON J.;KURZ, DAVID W.

  摘要：

  DOI：
• 作为试剂：
  描述：

  3,6-endomethylene-1,2,3,6-tetrahydrophthalic anhydride 在 N-羟基丁二酰亚胺 、 2-氨基-3-羟基丙酸甲酯 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 60.0h， 生成 (S)-2-((1R,2S,6R,7S)-3,5-Dioxo-4-aza-tricyclo[5.2.1.0^2,6]dec-8-en-4-yl)-3-hydroxy-propionic acid methyl ester
  参考文献：
  名称：

  Demonstration of endo-cis-(2S,3R)-Bicyclo[2.2.1]hept-5-en-2,3- dicarbonyl Unit as a Reverse-Turn Scaffold and Nucleator of Two-Stranded Parallel β-Sheets:  Design, Synthesis, Crystal Structure, and Self-Assembling Properties of Norborneno Peptide Analogues

  摘要：

  endo-cis-(2S,3R)-Bicyclo[2.2.1]hept-5-en (norbornene) dicarbonyl unit with a built-in U-architecture has been demonstrated to be an excellent reverse-turn molecular scaffold. A large variety of endo-cis-(2S,3R)-norborneno bispeptides containing almost all of the coded amino acids were synthesized and examined for conformational preferences by H-1 NMR, FT-IR, CD, and X-ray crystallographic studies. While FT-IR and H-1 NMR variable-temperature studies ruled out the presence of any significant amount of intramolecular hydrogen bonding in simple bispeptides (3a-h) (except in Aib bispeptide), the CD studies were clearly in favor of a beta-turn type structure. Single-crystal X-ray studies on Aib, Val and Leu containing norborneno bispeptides (3b-d) provided convincing proof for the presence of reverse-turn conformation. While the interstrand C-alpha-C-alpha' distances (5.2-5.7 Angstrom) were well within the range of those for beta-turn structures, no interstrand intramolecular hydrogen bonding was seen in Val and Leu bispeptides; the Aib bispeptide forms a seven-membered hydrogen-bonded ring, thus, showing that the norbornene (2S,3R)-dicarbonyl template assembles peptide chains in reverse-turn conformation by virtue of its built-in U-shaped architecture at these positions, and hydrogen bonding may not be necessary to stabilize the turn structure. The endo-cis-(2S,3R) orientation of bispeptide chains is essential for turn structure as shown by the crystal structure of trans-(2R, 3R) and trans-(2S,3S) derivative of Val bispeptide wherein the two peptide chains move away from each other with the C-alpha-C-alpha' distance increasing to 7.1-8.2 Angstrom. The norbornene 5,6-double bond was hydrogenated to 5,6-dihydro derivative which showed almost the same CD spectrum as its olefinic analogue. Oxidative cleavage [Ru (VIII)] of the 5,6-double bond in norborneno bispeptides, as demonstrated with Leu bispeptide, afforded novel cyclopentanoid peptide analogues. The promise of norbornene unit as a template for nucleating the formation of two-stranded parallel beta-sheets with minimum structural complexity is shown by the preparation of higher members of norborneno bispeptides with the general structure NBE(Pep)(2) [NBE = endo-cis-(2S,3R)-bicyclo[2.2.1]hept-5-en (norbornene) dicarbonyl unit; Pep = peptide strand with two, three, or four (same or different) amino acid residues]. In H-1 NMR, the high (3)J(HN alpha) values (7.0-9.3 Hz) observed for the amide protons (Table 5) coupled with the presence of medium to strong intrastrand sequential ROE connectivities d(alpha N(i,i+1)) spanning the entire three- or four-residue sequence in the peptide strands of 9a-e and 10 and the exhibition of relatively low-temperature coefficients (d delta/dT = -0.2 to -3.4 ppb/K) for amide protons in DMSO-d(6) solvent (Table 4) clearly suggested that hydrogen-bonded beta-sheet conformers dominate the population. FT-IR and CD studies provided further support for parallel beta-sheet structures. A particularly unique feature of the norborneno bispeptides is their strong tendency to self-assemble in the solid state.Thus, while endo-cis-(2S,3R)-Aib bispeptide (3b) forms 16-membered hydrogen bonded centrosymmetric dimers, the half-ester half-acid and the dicarboxylic acid derivatives of 3b self-assemble to form highly ordered hydrogen-bonded molecular ribbons. The Val and Leu cis-(2S, 3R)-bispeptides organize into hydrogen-bonded chains and the trans isomer of Val bispeptide self-assembles into hydrogen-bonded beta-sheet ribbon.

  DOI：

  10.1021/ja980143+

文献信息

• [EN] TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS PYRIDYLES À SUBSTITUTION TRIAZOLYLE UTILES COMME INHIBITEURS DE KINASES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013106614A1

  公开（公告）日：2013-07-18

  Compounds having the following formula:(I) wherein:A is an optionally substiuted triazole, or a stereoisomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation.

  具有以下公式的化合物：（I）其中：A 是一个可选地取代的三唑环，或者其立体异构体或药用可接受的盐，可用作激酶调节剂，包括 IRAK-4 调节。
• [EN] MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] COMPOSÉS MACROCYCLIQUES EN TANT QU'INHIBITEURS DE IRAK4 POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：BIOGEN IDEC INC

  公开号：WO2014143672A1

  公开（公告）日：2014-09-18

  Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein i.a. Ring A is phenylene or 5- to 6-membered heteroarylene; Ring B is phenylene, 5- to 6-membered heterocycloalkylene or 5- to 6-membered heteroarylen; R4 is absent, heteroarylene, arylene, C1-3 alkylene, or R4 and R3 taken together with the nitrogen to which they are bound form a 3- to 7-membered heterocycloalkyl ring; R5 is absent, C(0)NR51, NR52 or 0; R6 is C2-10 alkylene or alkenylene, wherein one or two of the carbon atoms in the alkylene chain is optionally replaced by an 0, S, SO, SO2 or NR61, and wherein two of the carbon atoms in the alkylene chain are optionally connected by a two or three carbon atom alkylene chain to form a 5- to 7-membered ring; R7 is absent, NR71 or O. The compounds are IRAK4 inhibitors useful for the treatment of inflammatory diseases.

  提供的是Formula (I)的化合物，或其药用盐，其中i.a.环A是苯基或5-至6-成员杂芳基；环B是苯基，5-至6-成员杂环烷基或5-至6-成员杂芳基；R4不存在，杂芳基，芳基，C1-3烷基，或R4和R3与它们结合的氮一起形成3-至7-成员杂环烷基环；R5不存在，C(0)NR51，NR52或0；R6是C2-10烷基或烯烃基，其中烷基链中的一个或两个碳原子可以选择性地被0、S、SO、SO2或NR61取代，烷基链中的两个碳原子可以选择性地通过一个两个或三个碳原子的烷基链连接在一起形成5-至7-成员环；R7不存在，NR71或O。这些化合物是对治疗炎症性疾病有用的IRAK4抑制剂。
• [EN] IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK<br/>[FR] DÉRIVÉS D'IMIDAZOLIDINONE COMME INHIBITEURS DE PERK
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2017046739A1

  公开（公告）日：2017-03-23

  The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Sträussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及取代咪唑烷酮衍生物。具体而言，该发明涉及根据式I（I）中R1、R2、R3、R4、R5、R6、R7、X、Y1、Y2和Z所定义的化合物。该发明的化合物是PERK的抑制剂，可用于治疗癌症、癌前综合征、阿尔茨海默病、神经病性疼痛、脊髓损伤、创伤性脑损伤、缺血性中风、中风、帕金森病、糖尿病、代谢综合征、代谢紊乱、亨廷顿病、克雅氏病、致命性家族性失眠、格斯特曼-施特劳斯勒-谢因克症候群及相关朊蛋白病、肌萎缩侧索硬化、进行性核上性麻痹、心肌梗死、心血管疾病、炎症、器官纤维化、肝脏慢性和急性疾病、脂肪肝病、肝脂肪变性、肝纤维化、肺部慢性和急性疾病、肺纤维化、肾脏慢性和急性疾病、肾脏纤维化、慢性创伤性脑病（CTE）、神经退行性疾病、痴呆症、额颞叶痴呆症、tau蛋白病、皮克氏病、尼曼-皮克氏病、淀粉样变性、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植以及器官移植用途中的运输。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制PERK活性和治疗相关疾病的方法。
• Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor
  作者：Hojong Yoon、Injae Shin、Yunju Nam、Nam Doo Kim、Kyung-Bok Lee、Taebo Sim

  DOI：10.1016/j.ejmech.2016.10.050

  日期：2017.1

  Transfection (RET) kinase frequently occur in human thyroid and lung cancers. An enormous effort has been devoted to discover potent and selective inhibitors of RET. Selective and potent inhibitors against constitutively active RET mutants are rare to date as identification of selective RET inhibitors is challenging. In a recent effort we identified a novel and specific RET inhibitor of 5-aminopyrazole-4-carboxamide

  在人类甲状腺癌和肺癌中，转染（RET）激酶中REarrange的激活突变经常发生。已经付出巨大的努力来发现有效的和选择性的RET抑制剂。迄今为止，针对组成型活性RET突变体的选择性和有效抑制剂很少见，因为选择性RET抑制剂的鉴定具有挑战性。在最近的努力中，我们鉴定了5-氨基吡唑-4-羧酰胺支架的新型和特异性RET抑制剂，其被设计用于增强吡唑并嘧啶支架的代谢稳定性。在本报告中描述的SAR研究中，我们鉴定了5-氨基吡唑-4-羧酰胺类似物15l，它具有较高的代谢稳定性。化合物15l对门卫突变体有效（IC 50 = 252 nM）以及野生型RET（IC 50  = 44 nM）。该物质有效抑制经野生型RET及其关守突变体（V804M）和甲状腺癌衍生的TT细胞转化的Ba / F3细胞的生长，但不影响亲代Ba / F3细胞和Nthy ori-3-1，正常甲状腺细胞。而且，在一组369种激酶上的全局激酶
• Synthesis, Degradation, and Antimicrobial Properties of Targeted Macromolecular Prodrugs of Norfloxacin
  作者：Eveline Roseeuw、Veerle Coessens、Anne-Marie Balazuc、Micheline Lagranderie、Pierre Chavarot、Augusto Pessina、Maria Grazia Neri、Etienne Schacht、Gilles Marchal、Dominique Domurado

  DOI：10.1128/aac.47.11.3435-3441.2003

  日期：2003.11

  Long-term antibiotic treatment is required to cure tuberculosis. Targeted antibiotics should improve the efficacy of treatment by concentrating the drugs close to the bacteria. The aim of the present study was to synthesize targeted conjugates. For this purpose, we used mannose as a homing device to direct norfloxacin into macrophages. Dextran was used as the polymer bearing both mannose and norfloxacin. Using different peptide spacer arms to link norfloxacin to dextran, we demonstrated that norfloxacin acts as an antibiotic only when it is released in its native form. Also, targeting by using mannose as a homing device is required to achieve antimycobacterial activity in vivo. Thus, norfloxacin, which is inactive against mycobacteria in its native form in vivo, can be transformed into an active drug by targeting.

  摘要 治愈结核病需要长期的抗生素治疗。靶向抗生素应通过将药物集中在细菌附近来提高疗效。本研究的目的是合成靶向共轭物。为此，我们使用甘露糖作为归巢装置，引导诺氟沙星进入巨噬细胞。右旋糖酐被用作同时含有甘露糖和诺氟沙星的聚合物。我们使用不同的肽间隔臂将诺氟沙星与右旋糖酐连接起来，证明诺氟沙星只有在以原生形式释放时才能发挥抗生素的作用。此外，要在体内发挥抗霉菌活性，还需要使用甘露糖作为归巢装置进行靶向。因此，诺氟沙星在体内以原生形式对分枝杆菌没有活性，但可以通过靶向转化为活性药物。